The 6-week, human intervention study featuring 20 subjects with pre-diabetes and mild to moderate hyperlipidemia found improvements in lipid profile and glycaemic levels among those taking the sesame seed blend (SesaVita) compared to placebo.
“The high performance liquid chromatography (HPLC) characterization of SesaVita revealed the presence of 71.11% w/w [mass concentration] total sesamin complex,” the researchers wrote in the study published this month in the Journal of Food Research.
“Thus, the lowering plasma cholesterol and glycaemic levels might be related to the amounts of sesamin complex from sesame seeds.”
The randomised, placebo-controlled, double-blind study comprised of 13 female and 7 male patients aged between 18 and 65 years, divided into study and placebo groups.
Their serum lipid profile and glycaemic levels were tested at 3 and 6 weeks.
“A statistical significant reduction was observed in low density lipoprotein cholesterol (LDL-C), total cholesterol (TC), oral glucose tolerance test (OGTT) and fasting blood sugar (FBS) levels during week 3 and 6 when treated with SesaVita extract,” they found.
SesaVita is manufactured by Indian firm, Olive Biosciences, which supported the study. The firm's VP of research and technical affairs, Shiva Prasad, PhD, was the lead author and said the findings offered an alternative for, “subjects who are advised with therapeutic lifestyle changes”.
Journal of Food Research
‘The Beneficial Effects of SesaVitaTM on Lipid Profiles and Blood Glucose Levels in Subjects With Prediabetes and Mild-To-Moderate Hyperlipidemia in India’
Authors: H. N. Shivaprasad, M. Bhanumathy, Ceyhun Tamer, G. Sushma, K. R. Raveendra, K. Venkateshwarlu